Clinical Trial Goal
To find out:
- The highest dose of VNX-101 that's safe to give
- If VNX-101 s safe and works well to treat ALL that has relapsed or is refractory in children and adults
You may be able to join this trial if you:
- Are 13 - 90 years old
- Have B-cell ALL that has relapsed or is refractory
- Have cancer cells that are CD19 positive. Your doctor can tell you this
- Do not have chronic graft-versus-host disease (GVHD)
- Agree to have other standard tests done to see if you can be in the clinical trial
Trial Details
VNX-101 is made up of gene-edited cells that increase GP101 in the body long-term.
You'll get:
You'll get:
- VNX-101 - Given 1 time as an intravenous (IV) infusion
You'll have biopsies to see how well the treatment is working. The clinical trial doctors will check your health for up to 15 years.
The Food and Drug Administration (FDA) has not yet approved VNX-101.
Watch a video about gene therapy
qKmeLLX26aw
Contacts
Allen Reha, 908-938-6019, allen.reha@vironexis.com
Recruitment Partner: PatientWing, 213-459-2979, studies@patientwing.com
Locations
Sponsors
lead: Vironexis Biotherapeutics Inc.
